
## Marianna Nodale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2554412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet, The, 2010, 375, 743-751.	13.7	429
2	Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ: British Medical Journal, 2011, 342, d1855-d1855.	2.3	217
3	Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Diabetes Care, 2014, 37, 1204-1211.	8.6	193
4	Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes. Diabetes Care, 2013, 36, 838-844.	8.6	144
5	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes and Endocrinology,the, 2014, 2, 701-709.	11.4	140
6	Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Research and Care, 2014, 2, e000025.	2.8	132
7	Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes. Diabetes Care, 2011, 34, 406-411.	8.6	115
8	Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study. Diabetes Care, 2014, 37, 1931-1937.	8.6	113
9	Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes. Diabetes Care, 2011, 34, 2527-2529.	8.6	101
10	Day and Night Closed-Loop Control in Adults With Type 1 Diabetes. Diabetes Care, 2013, 36, 3882-3887.	8.6	95
11	Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Critical Care, 2013, 17, R159.	5.8	94
12	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
13	Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia, 2012, 55, 282-293.	6.3	85
14	Automated Overnight Closed-Loop Glucose Control in Young Children with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 419-424.	4.4	52
15	Modelling of autumn plankton bloom dynamics. Journal of Plankton Research, 2006, 28, 209-220.	1.8	51
16	Feasibility of Closed-Loop Insulin Delivery in Type 2 Diabetes: A Randomized Controlled Study. Diabetes Care, 2014, 37, 1198-1203.	8.6	49
17	Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatric Diabetes, 2012, 13, 449-453.	2.9	48
18	Assessing Performance of Closed-Loop Insulin Delivery Systems by Continuous Glucose Monitoring: Drawbacks and Way Forward. Diabetes Technology and Therapeutics, 2013, 15, 4-12.	4.4	48

MARIANNA NODALE

#	Article	IF	CITATIONS
19	Pharmacokinetics of Insulin Aspart in Pump-Treated Subjects With Type 1 Diabetes: Reproducibility and Effect of Age, Weight, and Duration of Diabetes. Diabetes Care, 2013, 36, e173-e174.	8.6	47
20	Evaluating the Accuracy and Large Inaccuracy of Two Continuous Glucose Monitoring Systems. Diabetes Technology and Therapeutics, 2013, 15, 143-149.	4.4	40
21	Accuracy of Subcutaneous Continuous Glucose Monitoring in Critically III Adults: Improved Sensor Performance with Enhanced Calibrations. Diabetes Technology and Therapeutics, 2014, 16, 97-101.	4.4	38
22	Suspended insulin infusion during overnight closedâ€loop glucose control in children and adolescents with Type 1 diabetes. Diabetic Medicine, 2010, 27, 480-484.	2.3	37
23	Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia, 2013, 56, 1108-1117.	6.3	37
24	Accuracy of Continuous Glucose Monitoring During Exercise in Type 1 Diabetes Pregnancy. Diabetes Technology and Therapeutics, 2013, 15, 223-229.	4.4	30
25	Safety of closedâ€loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, 2014, 16, 1174-1178.	4.4	29
26	Physical Activity Energy Expenditure and Glucose Control in Pregnant Women With Type 1 Diabetes. Diabetes Care, 2013, 36, 1095-1101.	8.6	22
27	Meta-Analysis of Overnight Closed-Loop Randomized Studies in Children and Adults with Type 1 Diabetes: The Cambridge Cohort. Journal of Diabetes Science and Technology, 2011, 5, 1352-1362.	2.2	20
28	Safety, efficacy and glucose turnover of reduced prandial boluses during closedâ€loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, 2015, 17, 1173-1179.	4.4	19
29	Plasma Câ€peptide concentration in women with Type 1 diabetes during early and late pregnancy. Diabetic Medicine, 2012, 29, e361-4.	2.3	10
30	Evaluating the Performance of a Novel Embedded Closed-loop System. Journal of Diabetes Science and Technology, 2014, 8, 267-272.	2.2	7
31	An Evaluation of "l, Pancreas―Algorithm Performance <i>In Silico</i> . Journal of Diabetes Science and Technology, 2009, 3, 857-862.	2.2	5
32	Glucose Turnover After Replacement of Usual Therapy by Insulin in Insulin-naive Type 2 Diabetes Subjects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2225-2232.	3.6	5
33	Response to Mitre et al.: "Analysis of Continuous Glucose Monitoring Data to Assess Outpatient Closed-Loop Studies: Considerations for Different Sensors― Diabetes Technology and Therapeutics, 2014, 16, 328-329.	4.4	0